Press Releases

  • 7
    Oct.
  • Mon, 01 May 17 16:01:00 -0400

    Nivalis Therapeutics Reports First Quarter 2017 Financial Results

    More...PDF(414Kb)

  • 7
    Oct.
  • Tue, 18 Apr 17 14:05:00 -0400

    Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

    More...PDF(414Kb)

  • 7
    Oct.
  • Thu, 23 Feb 17 16:05:00 -0500

    Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 13 Feb 17 16:05:00 -0500

    Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results

    More...PDF(414Kb)

  • 7
    Oct.
  • Thu, 12 Jan 17 16:10:00 -0500

    Nivalis Therapeutics Announces Corporate Restructuring

    More...PDF(414Kb)

  • 7
    Oct.
  • Tue, 03 Jan 17 18:00:00 -0500

    Nivalis Therapeutics Announces Review of Strategic Alternatives

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 28 Nov 16 16:05:00 -0500

    Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 14 Nov 16 16:05:00 -0500

    Nivalis Therapeutics Announces Completion of Enrollment in Second Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 07 Nov 16 16:05:00 -0500

    Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

    More...PDF(414Kb)

  • 7
    Oct.
  • Thu, 03 Nov 16 16:05:00 -0400

    Nivalis Therapeutics Announces Appointment of Cynthia Smith to Board of Directors

    More...PDF(414Kb)

  • 7
    Oct.
  • Wed, 02 Nov 16 16:05:00 -0400

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

    More...PDF(414Kb)

  • 7
    Oct.
  • Tue, 06 Sep 16 07:30:00 -0400

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 01 Aug 16 16:05:00 -0400

    Nivalis Therapeutics Reports Second Quarter 2016 Financial Results

    More...PDF(414Kb)

  • 7
    Oct.
  • Thu, 07 Jul 16 07:00:00 -0400

    Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

    More...PDF(414Kb)

  • 7
    Oct.
  • Wed, 06 Jul 16 16:05:00 -0400

    Nivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

    More...PDF(414Kb)

  • 7
    Oct.
  • Wed, 15 Jun 16 07:00:00 -0400

    Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference

    More...PDF(414Kb)

  • 7
    Oct.
  • Wed, 01 Jun 16 07:00:00 -0400

    Nivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 16 May 16 16:05:00 -0400

    Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

    More...PDF(414Kb)

  • 7
    Oct.
  • Mon, 02 May 16 16:05:00 -0400

    Nivalis Therapeutics Reports First Quarter 2016 Financial Results

    More...PDF(414Kb)

  • 7
    Oct.
  • Fri, 22 Apr 16 16:05:00 -0400

    Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    More...PDF(414Kb)

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.